Search Results - (Author, Cooperation:A. Algra)
-
1Latest Papers from Table of Contents or Articles in PressP. van der Harst ; W. Zhang ; I. Mateo Leach ; A. Rendon ; N. Verweij ; J. Sehmi ; D. S. Paul ; U. Elling ; H. Allayee ; X. Li ; A. Radhakrishnan ; S. T. Tan ; K. Voss ; C. X. Weichenberger ; C. A. Albers ; A. Al-Hussani ; F. W. Asselbergs ; M. Ciullo ; F. Danjou ; C. Dina ; T. Esko ; D. M. Evans ; L. Franke ; M. Gogele ; J. Hartiala ; M. Hersch ; H. Holm ; J. J. Hottenga ; S. Kanoni ; M. E. Kleber ; V. Lagou ; C. Langenberg ; L. M. Lopez ; L. P. Lyytikainen ; O. Melander ; F. Murgia ; I. M. Nolte ; P. F. O'Reilly ; S. Padmanabhan ; A. Parsa ; N. Pirastu ; E. Porcu ; L. Portas ; I. Prokopenko ; J. S. Ried ; S. Y. Shin ; C. S. Tang ; A. Teumer ; M. Traglia ; S. Ulivi ; H. J. Westra ; J. Yang ; J. H. Zhao ; F. Anni ; A. Abdellaoui ; A. Attwood ; B. Balkau ; S. Bandinelli ; F. Bastardot ; B. Benyamin ; B. O. Boehm ; W. O. Cookson ; D. Das ; P. I. de Bakker ; R. A. de Boer ; E. J. de Geus ; M. H. de Moor ; M. Dimitriou ; F. S. Domingues ; A. Doring ; G. Engstrom ; G. I. Eyjolfsson ; L. Ferrucci ; K. Fischer ; R. Galanello ; S. F. Garner ; B. Genser ; Q. D. Gibson ; G. Girotto ; D. F. Gudbjartsson ; S. E. Harris ; A. L. Hartikainen ; C. E. Hastie ; B. Hedblad ; T. Illig ; J. Jolley ; M. Kahonen ; I. P. Kema ; J. P. Kemp ; L. Liang ; H. Lloyd-Jones ; R. J. Loos ; S. Meacham ; S. E. Medland ; C. Meisinger ; Y. Memari ; E. Mihailov ; K. Miller ; M. F. Moffatt ; M. Nauck ; M. Novatchkova ; T. Nutile ; I. Olafsson ; P. T. Onundarson ; D. Parracciani ; B. W. Penninx ; L. Perseu ; A. Piga ; G. Pistis ; A. Pouta ; U. Puc ; O. Raitakari ; S. M. Ring ; A. Robino ; D. Ruggiero ; A. Ruokonen ; A. Saint-Pierre ; C. Sala ; A. Salumets ; J. Sambrook ; H. Schepers ; C. O. Schmidt ; H. H. Sillje ; R. Sladek ; J. H. Smit ; J. M. Starr ; J. Stephens ; P. Sulem ; T. Tanaka ; U. Thorsteinsdottir ; V. Tragante ; W. H. van Gilst ; L. J. van Pelt ; D. J. van Veldhuisen ; U. Volker ; J. B. Whitfield ; G. Willemsen ; B. R. Winkelmann ; G. Wirnsberger ; A. Algra ; F. Cucca ; A. P. d'Adamo ; J. Danesh ; I. J. Deary ; A. F. Dominiczak ; P. Elliott ; P. Fortina ; P. Froguel ; P. Gasparini ; A. Greinacher ; S. L. Hazen ; M. R. Jarvelin ; K. T. Khaw ; T. Lehtimaki ; W. Maerz ; N. G. Martin ; A. Metspalu ; B. D. Mitchell ; G. W. Montgomery ; C. Moore ; G. Navis ; M. Pirastu ; P. P. Pramstaller ; R. Ramirez-Solis ; E. Schadt ; J. Scott ; A. R. Shuldiner ; G. D. Smith ; J. G. Smith ; H. Snieder ; R. Sorice ; T. D. Spector ; K. Stefansson ; M. Stumvoll ; W. H. Tang ; D. Toniolo ; A. Tonjes ; P. M. Visscher ; P. Vollenweider ; N. J. Wareham ; B. H. Wolffenbuttel ; D. I. Boomsma ; J. S. Beckmann ; G. V. Dedoussis ; P. Deloukas ; M. A. Ferreira ; S. Sanna ; M. Uda ; A. A. Hicks ; J. M. Penninger ; C. Gieger ; J. S. Kooner ; W. H. Ouwehand ; N. Soranzo ; J. C. Chambers
Nature Publishing Group (NPG)
Published 2012Staff ViewPublication Date: 2012-12-12Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Animals ; Cell Cycle/genetics ; Cytokines/metabolism ; Drosophila melanogaster/genetics ; Erythrocytes/cytology/*metabolism ; Female ; Gene Expression Regulation/genetics ; *Genetic Loci ; *Genome-Wide Association Study ; Hematopoiesis/genetics ; Hemoglobins/genetics ; Humans ; Male ; Mice ; Organ Specificity ; *Phenotype ; Polymorphism, Single Nucleotide/genetics ; RNA Interference ; Signal Transduction/geneticsPublished by: -
2Articles: DFG German National LicensesStaff View
ISSN: 1432-1440Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: -
3Articles: DFG German National LicensesStaff View
ISSN: 1433-0407Keywords: Schlüsselwörter Sekundärprävention ; Insult ; Antikoagulation ; Dipyridamol ; ESPRIT ; Key words Prevention ; Stroke ; Anticoagulant ; DipyridamoleSource: Springer Online Journal Archives 1860-2000Topics: MedicineDescription / Table of Contents: Summary The European and Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) is a randomised clinical trial in which patients with cerebral ischaemia of arterial origin will be randomised between oral anticoagulation (international normalized ratio (INR): 2.0–3.0), the combination of acetylsalicylic acid (in any dose between 30 and 325 mg per day) plus dipyridamole (400 mg daily) and acetylsalicylic acid only (in any dose between 30 and 325 mg per day). It is planned to enroll 4500 patients with a mean follow-up of three years. Primary outcome is the composite event of vascular death, stroke, myocardial infarction, or major bleeding complication; outcome assessment will be blinded. ESPRIT is an international, multicentre study in which 60–80 hospitals in the Netherlands and other countries in Europe and Australia will participate.Notes: Zusammenfassung Die Studie „European and Australian Stroke Prevention in Reversible Ischaemia Trial” (ESPRIT) ist eine randomisierte klinische Studie, in der Patienten nach ischämischem zerebralem Insult zwischen niedrig dosierter oraler Antikoagulation (INR: 2.0–3.0), der Kombinationstherapie mit Acetylsalicylsäure (30–325 mg pro Tag) plus Dipyridamol (400 mg pro Tag) oder Monotherapie mit Acetylsalicylsäure (30–325 mg pro Tag) randomisiert werden. An der Studie sollen 4500 Patienten teilnehmen, die durchschnittliche Behandlungsdauer beträgt 3 Jahre. Die Hauptpunkte der Studie sind „kardiovaskulärer Tod, nicht tödlicher Insult oder Myokardinfarkt, oder eine ernsthafte Blutungskomplikation”, die Beurteilung der Hauptendpunkte erfolgt blind. ESPRIT ist eine internationale, multizentrische Studie, an der 60–80 Krankenhäuser in den Niederlanden und anderen europäischen Ländern und in Australien teilnehmen werden.Type of Medium: Electronic ResourceURL: -
4Articles: DFG German National LicensesStaff View
ISSN: 1432-0630Keywords: 79.20N ; 35.80 ; 41.80GSource: Springer Online Journal Archives 1860-2000Topics: Mechanical Engineering, Materials Science, Production Engineering, Mining and Metallurgy, Traffic Engineering, Precision MechanicsPhysicsNotes: Abstract An apparatus is described for low energy (0.1–10 keV) ion scattering (LEIS) experiments. A time of flight (TOF) spectrometer is incorporated in the system to be able to measure the energy of particles in the neutral state after scattering. The energy resolution ΔE/E of the TOF spectrometer is discussed and found to be 0.5% (FWHM). This is sufficient for our scattering experiments. An electrostatic analyzer (ESA) is used to measure the energy of scattered ions [ΔE/E=0.5% (FWHM)]. Experiments show that in general the ion dose needed to obtain a TOF spectrum (2×1010 ions/cm2) is much smaller than the dose needed for an ESA-spectrum (6×1013 ions/cm2). The ion spectra measured with the TOF spectrometer, by subtracting the neutral yield from the total yield, as well as with the ESA are found to agree quite well. This provides a way to calibrate the TOF spectrometer. The determination of the ion fraction of scattered particles is discussed [10 keV40Ar+ on Cu(100), scattering angle 30°]. It is shown that the TOF spectrometer is able to measure light recoil particles (e.g. hydrogen) from a heavy substrate. In the analysing system is, in addition to the TOF spectrometer, also incorporated a stripping cell to measure the energy of neutral scattered particles. An energy spectrum of neutral scattered particles measured with both methods is shown.Type of Medium: Electronic ResourceURL: -
5Articles: DFG German National LicensesStaff View
ISSN: 1432-1459Keywords: Key words Intraventricular ¶hemorrhage ; Subarachnoid ¶hemorrhage ; Intracerebral ¶hemorrhage ; Extraventricular drainage ; FibrinolysisSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Severe intraventricular hemorrhage caused by extension from subarachnoid hemorrhage or intracerebral hemorrhage leads to hydrocephalus and often to poor outcome. We conducted a systematic review to compare conservative treatment, extraventricular drainage, and extraventricular drainage combined with fibrinolysis. We carried out a search in Medline of the literature between January 1966 and December 1998 and an additional hand-search from January 1990 to December 1998. Pharmaceutical companies were contacted to gather unpublished data. We reviewed the reference lists of all relevant articles. Two authors independently assessed eligibility of the studies and extracted data on characteristics of study design, patients, and treatment. Patients with primary intraventricular hemorrhage were excluded. Main outcome measures were death and poor outcome (defined as death or dependency) at the end of follow-up. No randomized clinical trial has yet been conducted so far, and we therefore reviewed only observational studies. The case fatality rate for conservative treatment (ten studies) was 78%. For extraventricular drainage (seven studies) it was 58% [relative risk versus conservative treatment (RR) 0.74; 95% confidence interval (CI) 0.55–0.99]. For extraventricular drainage with fibrinolytic agents (five studies) the case fatality rate was 6% (RR 0.08; 95% CI 0.02–¶0.24). The poor outcome rate for conservative treatment was 90%, that for extraventricular drainage 89% (RR 0.98; 95% CI 0.75–1.30) and that for extraventricular drainage with fibrinolytic agents 34% (RR 0.38; 95% CI 0.21–0.68). All RR values remained essentially the same after adjusting for age, sex, World Federation of Neurological Surgeons scale, study design, and year of publication for the studies that provided these data. Outcome is thus poor in patients with intraventricular extension of subarachnoid or intracerebral hemorrhage. This meta-analysis suggests that treatment with ventricular drainage combined with fibrinolytics may improve outcome for such patients, although this impression is derived only from an indirect comparison between observational studies. ¶A randomized clinical trial is warranted.Type of Medium: Electronic ResourceURL: -
6Articles: DFG German National LicensesStaff View
ISSN: 1432-1459Keywords: Key words Thunderclap headache ; Follow-upSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Follow-up studies of idiopathic thunderclap headache (ITH) have found no subsequent subarachnoid hemorrhage (SAH) or other serious neurological disease, but the effect on life-style has not been studied. To assess the long-term outcome of patients with ITH in general practice we prospectively followed 93 patients with an episode of ITH during 1988–1993, of whom 77 were referred to hospital. ITH was defined as a sudden, unusually severe headache that started within 1 min, lasted at least 1 h, and for which no underlying cause was found. These patients were treated in 252 general practices. Outcome measures were subsequent SAH, subsequent headaches, absence from work, and diminished daily functioning. Patients were followed up by their general practitioner for a median of 5 years (range 1–10). Three patients died, all from nonneurological diseases. No subsequent SAH was diagnosed in any of the 93 patients. Recurrent attacks of ITH occurred in 8 patients, and 13 developed new tension headache or migraine. Absence from work because of headache was recorded in 11 patients, and in the overall group 6 patients were dependent on welfare. In only one-half of patients (n=52) did the general practitioner judge the level of daily functioning to be similar to that before the index episode of ITH. Thus, although no episodes of SAH occurred after ITH during long-term follow-up, one-half of patients with ITH had a lower level of daily functioning, and one-eighth had reduced working capacity, specifically because of headache.Type of Medium: Electronic ResourceURL: -
7Articles: DFG German National LicensesSimons, P.C.G. ; Algra, A. ; van de Laak, M.F. ; Grobbee, D.E. ; van der Graaf, Y.
Springer
Published 1999Staff ViewISSN: 1573-7284Keywords: Atherosclerosis ; Cardiovascular disease ; Cohort study ; Risk factors ; Secondary preventionSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract The Second Manifestations of ARTerial disease (SMART) study is a single-centre prospective cohort study among patients, newly referred to the hospital with (1) clinically manifest atherosclerotic vessel disease, or (2) marked risk factors for atherosclerosis. The first objectives of the SMART study are to determine the prevalence of concomitant arterial disease at other sites, and risk factors in patients presenting with a manifestation of arterial disease or vascular risk factor and to study the incidence of future cardiovascular events and its predictors in these high-risk patients. At least 1000 patients, aged 18 to 80 years, will undergo baseline examinations, including a questionnaire on cardiovascular disease, height, weight and blood pressure measurements, blood tests for glucose, lipids, creatinine and homocysteine, urinary tests for microproteinuria, resting twelve-lead electrocardiogram, ultrasound scanning of the abdominal aorta, kidneys and the carotid arteries, measurements of common carotid intima-media thickness and arterial stiffness, and a treadmill test to assess atherosclerosis of the leg arteries. Abnormal findings are reported to the treating specialist and general practitioner with a treatment suggestion according to current practice guidelines. Recruitment and baseline examinations began in September 1996. All cohort members will be followed for clinical cardiovascular events for a minimum of three years. In the scope of secondary prevention, the study is expected to support the design of solid based screening and treatment programmes and evidence-based cardiovascular medicine to reduce morbidity and mortality, and improve quality of life, in high-risk patients.Type of Medium: Electronic ResourceURL: